Vikki Christian 5/16/22 Vikki Christian 5/16/22

Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

Lara Wilson 4/20/22 Lara Wilson 4/20/22

Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1

Lara Wilson 4/19/22 Lara Wilson 4/19/22

Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium on Myeloid Checkpoint Therapeutics in Cancer

Vikki Christian 4/12/22 Vikki Christian 4/12/22

Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors

Vikki Christian 4/8/22 Vikki Christian 4/8/22

Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the AACR 2022 Annual Meeting

Vikki Christian 3/9/22 Vikki Christian 3/9/22

Immune-Onc Therapeutics Announces Preclinical and Clinical Poster Presentations for IO-108, a Novel Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the AACR 2022 Annual Meeting

Vikki Christian 2/28/22 Vikki Christian 2/28/22

Immune-Onc Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference and the Oppenheimer 32nd Annual Healthcare Conference

Vikki Christian 2/17/22 Vikki Christian 2/17/22

Immune-Onc Therapeutics Receives FDA Fast Track Designation for IO-202, the First Anti-LILRB4 Myeloid Checkpoint Inhibitor, for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

Guest User 1/31/22 Guest User 1/31/22

Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors

Guest User 1/10/22 Guest User 1/10/22

Immune-Onc Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Guest User 11/22/21 Guest User 11/22/21

Immune-Onc Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Conference

Guest User 11/9/21 Guest User 11/9/21

Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Guest User 10/13/21 Guest User 10/13/21

Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients With Advanced Solid Tumors

Guest User 8/12/21 Guest User 8/12/21

Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2, in Patients with Advanced Solid Tumors

Guest User 6/24/21 Guest User 6/24/21

Immune-Onc Therapeutics Expands Global Footprint and Appoints Maggie Gu as China General Manager

Guest User 5/4/21 Guest User 5/4/21

Immune-Onc Therapeutics Appoints Stuart Lutzker, M.D., Ph.D. to Scientific Advisory Board

Guest User 4/10/21 Guest User 4/10/21

Immune-Onc Therapeutics Announces First Public Presentation of Data for its Myeloid Checkpoint Inhibitor, IO-202, in Solid Tumors at AACR21

Guest User 3/30/21 Guest User 3/30/21

Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors

Guest User 11/10/20 Guest User 11/10/20

Immune-Onc Therapeutics Announces Orphan Drug Designation of IO-202 (Anti-LILRB4) for Treatment of AML and Poster Presentation at ASH 2020

Guest User 11/9/20 Guest User 11/9/20

Immune-Onc Therapeutics to Present Preclinical Data for IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4) in Solid Tumors, at SITC 2020